Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
ABO‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab MonotherapyIn: Thoracic Cancer , Jg. 16 2025, Nr. 6, e70037DOI (Open Access)
-
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceIn: Nature Cancer , Jg. 6 2025, Nr. 2, S. 307 – 322DOI (Open Access)
-
Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumorsIn: Med 2025 , in pressDOI (Open Access)
-
NeoTRACK trial : Neo adjuvant TiRagolumab, A tezolizumab and Chemotherapy-dissection of IO-efficacy in NSCLC by longitudinal tracKing-protocol of a non-randomised, open-label, single-Arm, phase II studyIn: BMJ Open , Jg. 15 2025, Nr. 3, e096617DOI (Open Access)
-
Oligometastatic non-small cell lung cancer : Impact of local and contemporary systemic treatment approaches on clinical outcomeIn: International Journal of Cancer , Jg. 156 2025, Nr. 4, S. 776 – 787DOI (Open Access)
-
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024 : Targeted Therapies in Non-Small Cell Lung CancerIn: Oncology Research and Treatment , Jg. 48 2025, Nr. 3, S. 142 – 147DOI (Open Access)
-
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024 : Non-targeted therapy in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC) and Thymic Epithelial Tumors (TET)In: Oncology Research and Treatment 2025 , in pressDOI (Open Access)
-
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapyIn: Scientific Reports , Jg. 14 2024, Nr. 1, 13765DOI, Online Volltext (Open Access)
-
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapiesIn: European Journal of Cancer (EJC) , Jg. 200 2024, 113540DOI (Open Access)
-
Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations”In: European Journal of Cancer (EJC) , Jg. 213 2024, 115074DOI (Open Access)
-
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired ResistanceIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 6, S. 851 – 855
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 8, S. 1188 – 1193
-
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutationsIn: European Journal of Cancer (EJC) , Jg. 207 2024, 114158
-
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment : Comparison with Stage III DiseaseIn: Cancers , Jg. 16 2024, Nr. 6, 1174DOI (Open Access)
-
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON) : An International Real-World Safety and Efficacy AnalysisIn: International Journal of Molecular Sciences (IJMS) , Jg. 25 2024, Nr. 7, 3992DOI (Open Access)
-
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer : A randomized phase 2 trialIn: Nature Medicine , Jg. 30 2024, Nr. 6, S. 1602 – 1611DOI (Open Access)
-
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerIn: Journal of Thoracic Oncology , Jg. 19 2024, Nr. 5, S. 803 – 817DOI (Open Access)
-
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitorsIn: European Journal of Cancer (EJC) , Jg. 210 2024, 114268DOI (Open Access)
-
Small cell transformation in EGFR-mutated non-small cell lung cancer : DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapyIn: European Journal of Cancer (EJC) , Jg. 213 2024, 115065DOI (Open Access)
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics , Jg. 14 2024, Nr. 14, S. 5400 – 5412DOI, Online Volltext (Open Access)
-
Zielgerichtete Therapie des nichtkleinzelligen LungenkarzinomsIn: Die Onkologie , Jg. 30 2024, Nr. 9, S. 877 – 885
-
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 10, S. 1540 – 1549DOI (Open Access)
-
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)In: Oncology Research and Treatment , Jg. 46 2023, Nr. 3, S. 89 – 99
-
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 8, S. 5085 – 5094DOI (Open Access)
-
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsIn: Oncology Research and Treatment , Jg. 46 2023, Nr. 4, S. 140 – 150
-
Deep learning-based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancerIn: Journal of Cachexia, Sarcopenia and Muscle , Jg. 14 2023, Nr. 1, S. 545 – 552DOI, Online Volltext (Open Access)
-
Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological InpatientsIn: Cancers , Jg. 15 2023, Nr. 11, 3029DOI, Online Volltext (Open Access)
-
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 11, S. 9243 – 9252DOI (Open Access)
-
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 8, S. 4315 – 4325DOI (Open Access)
-
Impact of encorafenib on survival of patients with BRAFV⁶⁰⁰E-mutant metastatic colorectal cancer in a real-world settingIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 14, S. 12903 – 12912DOI (Open Access)
-
SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 8, S. 1191 – 1194DOI (Open Access)
-
Smaller panel, similar results : Genomic profiling and molecularly informed therapy in pancreatic cancerIn: ESMO Open , Jg. 8 2023, Nr. 3, 101539DOI (Open Access)
-
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapyIn: BMC Cancer , Jg. 22 2022, Nr. 1, 46DOI, Online Volltext (Open Access)
-
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer : focus on treatment selection and prognostic factorsIn: Immunotherapy , Jg. 14 2022, Nr. 12, S. 927 – 944DOI (Open Access)
-
Impact of endobiliary radiofrequency ablation on biliary drainage in patients with malignant biliary strictures treated with uncovered self-expandable metal stents : A randomized controlled multicenter trialIn: Gastrointestinal Endoscopy , Jg. 96 2022, Nr. 6, S. 970 – 979
-
Multimodal survival prediction in advanced pancreatic cancer using machine learningIn: ESMO Open , Jg. 7 2022, Nr. 5, 100555DOI, Online Volltext (Open Access)
-
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CTIn: Scientific Reports , Jg. 12 2022, Nr. 1, 17511DOI, Online Volltext (Open Access)
-
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsIn: Lung Cancer , Jg. 168 2022, S. 10 – 20
-
Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen LungenkarzinomsIn: Die Innere Medizin , Jg. 63 2022, Nr. 7, S. 717 – 723
-
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)In: Annals of Oncology , Jg. 33 2022, Nr. 6, S. 602 – 615DOI (Open Access)
-
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V⁶⁰⁰-mutated Squamous Cell Lung Cancer : Concurrent Evolvement of PTEN and MEK1 MutationsIn: Clinical Lung Cancer , Jg. 22 2021, Nr. 5, S. E668 – E672
-
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyIn: European Journal of Cancer (EJC) , Jg. 149 2021, S. 211 – 221
-
Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology , Jg. 147 2021, Nr. 2, S. 579 – 591DOI (Open Access)
-
DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patientsIn: European Journal of Cancer (EJC) , Jg. 147 2021, S. 142 – 150
-
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsIn: Journal of Thoracic Oncology , Jg. 16 2021, Nr. 11, S. 1952 – 1958DOI (Open Access)
-
HER2 mediates clinical resistance to the KRASG¹²C inhibitor sotorasib, which is overcome by co-targeting SHP2In: European Journal of Cancer (EJC) , Jg. 159 2021, S. 16 – 23
-
Patterns of nodal spread in stage III NSCLC : Importance of EBUS-TBNA and ¹⁸F-FDG PET/CT for radiotherapy target volume definitionIn: Radiation Oncology , Jg. 16 2021, Nr. 1, 176DOI, Online Volltext (Open Access)
-
Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive ChemoradiotherapyIn: Journal of Nuclear Medicine (JNM) , Jg. 62 2021, Nr. 12, S. 1684 – 1691DOI, Online Volltext (Open Access)
-
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer : The CEBIFOX TrialIn: Clinical Colorectal Cancer , Jg. 19 2020, Nr. 4, S. 236 – 247.e6
-
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expressionIn: Cancer Medicine , Jg. 9 2020, Nr. 13, S. 4527 – 4539DOI, Online Volltext (Open Access)
-
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutationIn: Lung Cancer , Jg. 139 2020, S. 165 – 168
-
Crizotinib in ROS1 and MET deregulated NSCLC-letterIn: Clinical Cancer Research , Jg. 26 2020, Nr. 7, S. 1774DOI (Open Access)
-
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancerIn: Lung Cancer , Jg. 149 2020, S. 10 – 16
-
Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer centerIn: Journal of Cancer Research and Clinical Oncology 2020DOI (Open Access)
-
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextIn: European Journal of Cancer (EJC) , Jg. 140 2020, S. 76 – 85
-
Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free rna for noninvasive early detection of cancerIn: Cancers , Jg. 12 2020, Nr. 2, S. 353DOI, Online Volltext (Open Access)
-
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations : results from the IMMUNOTARGET registryIn: Annals of Oncology , Jg. 30 2019, Nr. 8, S. 1321 – 1328DOI (Open Access)
-
Impact of RAS mutation subtype on clinical outcome : A cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancerIn: Oncogene , Jg. 38 2019, Nr. 16, S. 2953 – 2966
-
Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocolsIn: Journal of Cancer Research and Clinical Oncology , Jg. 145 2019, Nr. 2, S. 445 – 455
-
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancerIn: Annals of Oncology , Jg. 30 2019, Nr. 4, S. 655 – 657DOI (Open Access)
-
Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations : New Results from the Global IMMUNOTARGET RegistryIn: Journal of Thoracic Oncology , Jg. 13 2018, Nr. Suppl. 10, S. 367DOI (Open Access)
-
MET Expression in Advanced Non–Small-Cell Lung Cancer : Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyIn: Clinical Lung Cancer , Jg. 19 2018, Nr. 4, S. e441 – e463
-
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomasIn: International Journal of Cancer , Jg. 143 2018, Nr. 7, S. 1764 – 1773DOI (Open Access)
-
Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal CancerIn: Clinical Colorectal Cancer , Jg. 17 2018, Nr. 2, S. e331 – e352
-
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung AdenocarcinomaIn: Clinical Lung Cancer , Jg. 19 2018, Nr. 6, S. e879 – e884
-
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerIn: Journal of Thoracic Oncology , Jg. 12 2017, Nr. 1, S. 54 – 64DOI (Open Access)
-
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapyIn: OncoTarget , Jg. 8 2017, Nr. 28, S. 45898 – 45917DOI (Open Access)
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) , Jg. 49 2013, Nr. 15, S. 3076 – 3082
-
Rocket fuel for the quantification of S-nitrosothiols : highly specific reduction of S-nitrosothiols to thiols by methylhydrazineIn: Free Radical Research , Jg. 47 2013, Nr. 2, S. 104 – 115
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie , Jg. 35 2012, Nr. Suppl. 6, S. 204 – 204
-
Comprehensive molecular analysis in advanced thymic epithelial tumors uncovers germline alterations in one fifth of patients impacting therapy recommendations
57th European Society of Human Genetics (ESHG) Conference, June 1-4, 2024, Berlin, Germany,In: European Journal of Human Genetics , Jg. 32 2024, Nr. Supplement 2, S. 833 – 834(Open Access) -
Lung Cancer in Young Adults is Associated with Advanced Disease at Diagnosis and Increased Frequency of Targetable MutationsIn: Journal of Thoracic Oncology , Jg. 19 2024, Nr. Suppl. 10, S. S84 – S85
-
Treatment sequences in BRAF-V600-mutant non-small cell lung cancer : First-line targeted therapy versus first-line (chemo-) immunotherapy
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S827 – S828 -
68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer PatientsIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. 488 – S489
-
68Ga-Satoreotide PET for Staging of Small-Cell Lung Cancer PatientsIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. Suppl. 1, P165
-
Clinical characteristics and treatment outcome of FGFR1-3 fusions in patients with non-small cell lung cancer (NSCLC) : A multicenter analysis from National Network Genomic Medicine
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 146 – 147DOI (Open Access) -
Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations : Results from the RECAP study
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S793 – S794 -
Genomics-based characterization and personalized therapy of advanced thymic epithelial tumors
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 144DOI (Open Access) -
HER2-low as potential prognostic biomarker in patients (pts) with metastatic or recurrent Gastric Cancer (GC) or esophageal-gastric junction (AEG) adenocarcinoma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 117 – 118DOI (Open Access) -
Kreuzvalidierte Prognoseparameter C-reaktives Protein und Blutbild-Parameter im Verlauf der kurativ intendierten Radiochemotherapie bei Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) im Stadium IIIA-CIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 199 2023, Nr. Suppl. 1, S. S100 – S101DOI (Open Access)
-
Long-term Survival in Patients with oligometastatic Lung Cancer (cT4 or cN2-3, cM1a-c) after thoracic Chemoradiation, Metastasis-directed and Systemic Therapy compared with the Outcome in locally advanced Lung Cancer (cT4 or cN2-3, cM0)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 199 2023, Nr. Suppl. 1, S. S101 – S102DOI (Open Access)
-
A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology , Jg. 33 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1404DOI (Open Access) -
Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLCIn: Journal of Thoracic Oncology , Jg. 17 2022, Nr. 9, S. 611
-
Robuste und lang-andauernde Wirksamkeit der Durvalumab-Konsolidierung bei NSCLC im Stadium III nach Induktionschemotherapie und definitiver Radiochemotherapie : Fokus auf Behandlungsauswahl und prognostische Faktoren
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 198 2022, Nr. Supplement 1, S. S15DOI (Open Access) -
Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C InhibitionIn: Journal of Thoracic Oncology , Jg. 17 2022, Nr. 9, S. S586 – S587
-
EBUS-TBNA and [F-18] FDG-PET/CT for precise Target Volume Definition prior to Chemoradiotherapy : Lymphonodular Spreading Patterns in Stage III NSCLCIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 197 2021, Nr. Suppl. 1, S. 142
-
Re-Irradiation of cerebral Metastases after prophylactic Brain Skull irradiation in small-cell neuroendocrine Lung Cancer (SCLC)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 197 2021, Nr. Suppl. 1, S. 176
-
Response to treatment of uncommon EGFR mutations : a retrospective analysis from the German National Network Genomic Medicine Lung Cancer (nNGM)
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment , Jg. 44 2021, Nr. Supplement 2, S. 3 – 4DOI (Open Access) -
Treatment outcome and functional characterization of uncommon EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)In: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 15_Suppl, S. 9036 – 9036DOI (Open Access)
-
Patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) show highly favorable outcomes with treatment sequences provided at a comprehensive cancer center
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 137DOI (Open Access) -
The impact of needle choice on molecular analysis of ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in NSCLCIn: European Respiratory Journal (ERJ) , Jg. 56 2020, Nr. Suppl. 64DOI (Open Access)
-
Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX)In: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. 15 Suppl., S. e15121DOI (Open Access)
-
Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment , Jg. 41 2018, Nr. Suppl. 4, S. 289DOI (Open Access) -
Potentially Targetable Molecular Alterations in 70 Cases of Urachal Cancer
Geared to Learn ; USCAP 107th Annual Meeting ; March 17–23, 2018, Vancouver,In: Modern Pathology , Jg. 31 2018, Nr. Suppl. 2, S. 378DOI (Open Access) -
Predictive markers for immune checkpoint inhibitor therapy
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment , Jg. 41 2018, Nr. Suppl. 4, S. 12DOI (Open Access) -
Signaling network activation in colorectal cancer : p70S6K phosphorylation as a prognostic marker
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment , Jg. 41 2018, Nr. Suppl. 1, S. 55DOI (Open Access) -
Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin, Germany,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 – 119 -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 1, S. 92 -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Journal of Clinical Oncology (JCO) , Jg. 32 2014, Nr. 15, Suppl., S. 8109
-
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin, Germany,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 1, S. 2 – 3 -
Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ), one of the 11 Oncology Centers of Excellence in Germany
17 Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie , Jg. 36 2013, Nr. Suppl. 7, S. 263 -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Onkologie , Jg. 36 2013, Nr. Suppl. 7, S. 30
-
Try : a phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Journal of Thoracic Oncology , Jg. 8 2013, Nr. Suppl. 2, S. S914 – S915DOI (Open Access)
-
Oligometastatic non-small cell lung cancer : Impact of local and systemic treatment approaches on clinical outcome
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S828 -
Relapse after radiochemotherapy and consolidative Durvalumab in Stage III NSCLC – a retrospective analysis in a real-world setting
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 229DOI (Open Access) -
Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC) : Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S770DOI (Open Access)